SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

October 09, 2012 07:00 ET

Top Explosives Trace Detection Expert Joins Implant Sciences

Dr. Hacene Boudries, Formerly of Morpho Detection and GE Security, Fortifies Implant Sciences' Technology Team

WILMINGTON, MA--(Marketwire - Oct 9, 2012) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced today the appointment of Dr. Hacene Boudries as Director of Technology, marking the latest in a series of high-level industry experts added to Implant Sciences' management team.

Dr. Boudries was most recently with Morpho Detection Inc. where he was Director, Research & Technology, Chemical/Biological Detection & Chemical Sensing at Morpho Detection's Advanced Technology Programs. At Morpho he took products from proof of concept and R&D prototype to commercialization. Previously, Dr. Boudries was Research and Development Manager in charge of Chemical/Biological Detection at General Electric Security. He has worked at the Massachusetts Institute of Technology's Department of Chemical Engineering as a Research Engineer and served as Principal Scientist at Aerodyne Research, Inc. Dr. Boudries holds a Master of Science and a PhD in Physical Chemistry from the University of Paris VII in Paris, France.

"Dr. Boudries will be a key contributor to our strategy of introducing next generation technology to the security market. His strong record of success with trace and advanced chemical detection coupled with extensive experience with the TSA and other government certification initiatives will make him an excellent addition to our technical team," stated Implant Sciences' Vice President of Technology, Todd Silvestri.

"We continue to attract some of the top talent in our industry. Our success in drawing experienced personnel from larger companies in the homeland security market gives us a strong framework for growth. The team we have assembled inspires confidence in our ability to strategically advance in our industry," added Implant Sciences' President and CEO, Glenn D. Bolduc.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    Email Contact


    Investor Contact:
    Laurel Moody
    Email Contact